Research article |

The Lancet: Rational use of moxifloxacin for tuberculosis treatment

Authors: Helen Cox, Nathan Ford, Salmaan Keshavjee, Cheryl McDermid, Tido von Schoen-Angerer, Carole Mitnick, Eric Goemaere

From: The Lancet Infectious Diseases, Volume 11, Issue 4, Pages 259 - 260, April 2011


Despite intensified efforts in recent years, tuberculosis is uncontrolled in many regions. Although drug-susceptible tuberculosis is a treatable disease, the 6 month duration of therapy, often administered under daily direct observation, can result in poor outcomes because of the demands that this regimen places on patients and health systems. Therapy for multidrug-resistant (MDR) tuberculosis is even more demanding: it lasts 2 years and is associated with distressing and often severe side-effects. Unsurprisingly, treatment outcomes for MDR tuberculosis are considerably poorer than for drug-susceptible tuberculosis, even in optimum conditions. For full text, visit The Lancet site (login required) or download PDF above.